Magenta Therapeutics’ Expanded Stem Cell Product, MGTA-456, Engrafts in 100% of Patients, Leading to Robust … – Business Wire (press release)
|
Magenta Therapeutics' Expanded Stem Cell Product, MGTA-456, Engrafts in 100% of Patients, Leading to Robust …
Business Wire (press release) CAMBRIDGE, Mass.–(BUSINESS WIRE)–Magenta Therapeutics, a biotechnology company developing therapeutics to improve and extend the use of curative bone marrow transplant for more patients, today reported Phase 2 clinical data from its MGTA-456 … |
